| Basics |
Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals Inc is the RNA-targeted drug discovery and development company. Its broad pipeline consists of close to 32 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe, and rare diseases.
|
| IPO Date: |
December 22, 2015 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$9.76B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.88 | 1.99%
|
| Avg Daily Range (30 D): |
$0.98 | 2.14%
|
| Avg Daily Range (90 D): |
$0.69 | 1.70%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.17M |
| Avg Daily Volume (30 D): |
2.46M |
| Avg Daily Volume (90 D): |
1.76M |
| Trade Size |
| Avg Trade Size (Sh.): |
84 |
| Avg Trade Size (Sh.) (30 D): |
70 |
| Avg Trade Size (Sh.) (90 D): |
65 |
| Institutional Trades |
| Total Inst.Trades: |
10,822 |
| Avg Inst. Trade: |
$2.58M |
| Avg Inst. Trade (30 D): |
$3.15M |
| Avg Inst. Trade (90 D): |
$3.27M |
| Avg Inst. Trade Volume: |
.06M |
| Avg Inst. Trades (Per Day): |
4 |
| Market Closing Trades |
| Avg Closing Trade: |
$6M |
| Avg Closing Trade (30 D): |
$13.52M |
| Avg Closing Trade (90 D): |
$11.2M |
| Avg Closing Volume: |
138.44K |
|
|
| Financials |
| |
TTM |
Q2 2025 |
Q1 2025 |
|
Basic EPS
|
$-1.76
|
$.78
|
$-.93
|
|
Diluted EPS
|
$-1.76
|
$.7
|
$-.93
|
|
Revenue
|
$ 944.05M
|
$ 452.05M
|
$ 131.61M
|
|
Gross Profit
|
$ 933.54M
|
$ 447.9M
|
$ 130.15M
|
|
Net Income / Loss
|
$ -268.22M
|
$ 123.55M
|
$ -146.94M
|
|
Operating Income / Loss
|
$ -266.52M
|
$ 139.82M
|
$ -146.86M
|
|
Cost of Revenue
|
$ 10.52M
|
$ 4.15M
|
$ 1.46M
|
|
Net Cash Flow
|
$ 2.62M
|
$ 32.52M
|
$ 21.88M
|
|
PE Ratio
|
|
|
|
|
|
|
